264 related articles for article (PubMed ID: 27462147)
1. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.
Nishikawa A; Ishida T; Taketsuna M; Yoshiki F; Enomoto H
Clin Interv Aging; 2016; 11():913-25. PubMed ID: 27462147
[TBL] [Abstract][Full Text] [Related]
2. The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report.
Yamamoto T; Taketsuna M; Guo X; Sato M; Sowa H
J Bone Miner Metab; 2014 Nov; 32(6):699-708. PubMed ID: 24368586
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study.
Nishikawa A; Yoshiki F; Taketsuna M; Kajimoto K; Enomoto H
Clin Interv Aging; 2016; 11():1653-1659. PubMed ID: 27895472
[TBL] [Abstract][Full Text] [Related]
4. Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis.
Soen S; Fujiwara S; Takayanagi R; Sato M; Tsujimoto M; Yamamoto T; Enomoto H; Krege JH
Curr Med Res Opin; 2015; 31(9):1771-9. PubMed ID: 26189932
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS).
Soen S; Fujiwara S; Takayanagi R; Kajimoto K; Tsujimoto M; Kimura S; Sato M; Krege JH; Enomoto H
Curr Med Res Opin; 2017 Nov; 33(11):2049-2056. PubMed ID: 28699789
[TBL] [Abstract][Full Text] [Related]
6. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: Post hoc analysis of a prospective observational study.
Yoshiki F; Nishikawa A; Taketsuna M; Kajimoto K; Enomoto H
J Orthop Sci; 2017 Mar; 22(2):330-338. PubMed ID: 28038880
[TBL] [Abstract][Full Text] [Related]
8. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
[TBL] [Abstract][Full Text] [Related]
9. Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation.
Yamamoto T; Tsujimoto M; Sowa H
Clin Interv Aging; 2015; 10():1101-9. PubMed ID: 26185429
[TBL] [Abstract][Full Text] [Related]
10. 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk.
Sugimoto T; Shiraki M; Fukunaga M; Hagino H; Sone T; Nakano T; Kishimoto H; Ito M; Yoshikawa H; Kishida M; Irie C; Nakamura T
Adv Ther; 2017 Jul; 34(7):1727-1740. PubMed ID: 28631217
[TBL] [Abstract][Full Text] [Related]
11. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
[TBL] [Abstract][Full Text] [Related]
12. [Daily subcutaneous injection of teriparatide : the progress and current issues].
Yano S; Sugimoto T
Clin Calcium; 2014 Jan; 24(1):35-43. PubMed ID: 24369278
[TBL] [Abstract][Full Text] [Related]
13. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
14. Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study.
Sugimoto T; Shiraki M; Fukunaga M; Kishimoto H; Hagino H; Sone T; Nakano T; Ito M; Yoshikawa H; Minamida T; Tsuruya Y; Nakamura T
Osteoporos Int; 2019 Nov; 30(11):2321-2331. PubMed ID: 31392401
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study.
Välimäki VV; Mäkitie O; Pereira R; Laine C; Wesseling-Perry K; Määttä J; Kirjavainen M; Viljakainen H; Välimäki MJ
J Clin Endocrinol Metab; 2017 Feb; 102(2):535-544. PubMed ID: 27732335
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk.
Ifuku E; Yoshimura T; Uzawa T; Hokonohara T
Osteoporos Sarcopenia; 2019 Jun; 5(2):44-50. PubMed ID: 31338434
[TBL] [Abstract][Full Text] [Related]
20. Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS).
Aloumanis K; Kapetanos G; Bartzis N; Drossinos V;
BMC Musculoskelet Disord; 2015 Jun; 16():136. PubMed ID: 26044820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]